AbCellera Biologics Inc.

ABCL Healthcare Biotechnology

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.80 0.88 −6.94%
Market cap
$4.1B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
5/9
Altman Z
1.66
Beneish M
−1.06
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
42.56 13.60 13.35 36.25
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(28.58) (29.40) (31.55) 92.53
P/B ratio
1.56 1.06 1.13 2.68
Price to Tangible BV
1.71 1.16 1.24 2.96
EV/Sales
27.92 6.21 6.71 27.76
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(9.43) (3.55) (3.47) (19.35)
EV/FCF
(6.31) (2.63) (2.76) (14.96)
Quick Ratio
8.17 9.60 11.98 10.97
Current Ratio
10.10 11.32 14.05 12.77
Net Debt/EBITDA
7.54 27.05 10.84 10.47
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.03 0.06 0.06 0.05
Operating CF/Net income
0.92 3.88 0.78 (0.47)
Capex/Depreciation
(1.23) (1.24) (0.44) (0.24)
Research and Development Expense of Revenue
614.49% 111.68% 561.18% 1,135.48%
Selling, General and Administrative Expense of Revenue
278.70% 38.39% 148.33% 341.98%
Intangible Assets out of Total Assets
0.06 0.06 0.07 0.06
Share Based Compensation of Revenue
155.16% 28.77% 144.47% 303.36%
Graham Net Nets
0.20 0.33 0.28 0.11
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(11.33%) (14.33%) (13.75%) (6.88%)
Free Cash Flow Yield
(10.39%) (17.34%) (18.19%) (5.12%)
Revenue per Share
0.03 0.15 0.03 0.01
Operating CF per Share
(0.18) (0.12) (0.11) 0.08
Capex per Share
(0.03) (0.03) (0.01) (0.01)
Free Cash Flow per Share
(0.21) (0.15) (0.12) 0.08
Cash per Share
1.74 1.87 1.75 1.85
Shareholders Equity per Share
3.23 3.24 3.10 2.93
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
3.23 3.24 3.10 2.93
Free Cash Flow
(61.52) (44.59) (37.35) 23.79
Working Capital
626.34 663.93 617.30 626.04
Capital Expenditures
(8.93) (9.84) (3.83) (2.13)
Net Current Asset Value
303.19 338.19 295.57 267.68
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
1.00 0.22 0.46 0.53
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
36.41 45.95 38.38 32.95
Average Payables
53.45 52.89 43.70 41.28
Average Assets
1,374.41 1,358.75 1,325.66 1,354.82
Average Common Equity
1,021.07 1,011.49 980.53 951.55

Fold the line items

Columns are period end dates